Lymphoplasmacytic Lymphoma
52
14
20
24
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
13 trials with published results (25%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
5.8%
3 terminated out of 52 trials
88.9%
+2.3% vs benchmark
4%
2 trials in Phase 3/4
54%
13 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 24 completed trials
Clinical Trials (52)
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
64Cu-LLP2A for Imaging Hematologic Malignancies
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Study of SGR-1505 in Mature B-Cell Neoplasms
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy